Login to Your Account



Archemix Signs Aptamer Deal With Elan For Up To $350M

By Jennifer Boggs


Friday, July 14, 2006
In one of its largest deals to date, Archemix Corp. partnered with Irish firm Elan Corp. plc to develop up to three aptamer-based drugs against autoimmune inflammatory disease and could earn more than $350 million in potential milestones. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription